Novavax, Inc. is a late-stage biotechnology company that creates next-generation vaccines for severe infectious diseases, and contributes to global public health. Listed on the NASDAQ exchange under the ticker symbol NVAX, Novavax first came to prominence for leading the fight against coronavirus disease 2019 (COVID-19) with its vaccine candidate, NVX-CoV2373.
Headquartered in Gaithersburg, Maryland, Novavax was founded in 1987 and has remained committed to using its proprietary recombinant nanoparticle vaccine technology to replicate antigens derived from the virus. This technique is used to develop vaccines that can target a wide array of infectious diseases including COVID-19, seasonal influenza, and respiratory syncytial virus (RSV).
NVX-CoV2373 is the flagship COVID-19 vaccine candidate of Novavax. It is a protein-based vaccine engineered from the genetic sequence of the SARS-CoV-2 virus. This vaccine has been designed to generate enhanced immune responses and to generalise a high level of efficacy. As of late 2021, the vaccine is undergoing Phase 3 clinical trials in locations around the globe.
Moreover, Novavax is also recognized for its potency against influenza with its NanoFlu, a recombinant, quadrivalent, nanoparticle flu vaccine. In 2020, the US Food and Drug Administration (FDA) granted NanoFlu a fast-track designation, thereby accelerating its path to regulatory approval.
Behind its solid scientific and operational development, there lies Novavax's commitment to global health. The company is a member of the Coalition for Epidemic Preparedness Innovations (CEPI), and also works in collaboration with international organizations such as the Bill & Melinda Gates Foundation to ensure affordable and equitable access to vaccines to people all around the world.
Financially, the company has experienced a significant surge in its stock price on the back of its successful advances in vaccine development. However, it has also faced numerous challenges and criticisms, particularly towards its ability to scale up manufacturing.
In the future, Novavax aims to push the boundaries of vaccine science and deliver on promises of creating an enhanced global health landscape. Its core focus extends beyond its current products to involve substantial investment in research and development, with the mission of discovering, testing, and bringing to market more novel vaccines for the betterment of humanity.